Business
Ovid Therapeutics Announces Multiple Presentations on the 2020 American Academy of Neurology Science Highlights Platform
NEW YORK, June 08, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that
About this update from Ovid Therapeutics Inc.
[{"type":"text","content":"NEW YORK, June 08, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced multiple presentations across its rare neurological disease platform are available on the 2020 American Academy of Neurology (AAN) Science Highlights platform. The presentations were originally slated for discussion at the AAN 72nd Annual Meeting scheduled for April 25-May 1, which was cancelled due to the COVID-19 pandemic. The abstracts were also published in the online supplement to Neurology.\n The presentations available on the AAN Science Highlights online platform include the following: Presentations on OV101 (gaboxadol) in Neurodevelopmental Disorders: Title: The adaptation and utility of the Clinical Global Impression scale for studying treatment outcomes in neurodevelopmental conditions Topic: Child Neurology and Developmental Neurology Title: The pivotal Phase 3 NEPTUNE trial investigating OV101 (gaboxadol) in Angelman syndrome: study overview and rationale Topic: Child Neurology and Developmental Neurology Title: Evidence of pharmacodynamic tolerance during repeated daily OV101 (gaboxadol) exposure in individuals with Angelman syndrome Topic: Child Neurology and Developmental Neurology Title: Physiologically based pharmacokinetic modeling (PBPK) for OV101 (gaboxadol) exposure in children with Angelman syndrome Topic: Child Neurology and Developmental Neurology Title: Caregiver insight on the core domains in Angelman syndrome Topic: Child Neurology and Developmental Neurology Title: Quality of life in adolescent and adult individuals with Angelman syndrome: Baseline results from the Phase 2 STARS study Topic: Child Neurology and Developmental Neurology Title: Concomitant medication in adolescent and adult individuals with Angelman syndrome: Baseline results from the Phase 2 STARS study Topic: Child Neurology and Developmental Neurology Title: The Phase 2a ROCKET trial investigating OV101 (gaboxadol) in adolescents and young adults with Fragile X syndrome Topic: Child Neurology and Developmental Neurology Presentations on OV935/TAK935 (soticlestat) in Rare Developmental and Epileptic Encephalopathies (DEE): Title: Initial data from the ongoing ENDYMION open-label extension trial of soticlestat ...